Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-07-11
2006-07-11
Huang, Evelyn Mei (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S307000, C546S176000, C546S149000, C546S329000
Reexamination Certificate
active
07074806
ABSTRACT:
A compound of Formula (IA) or Formula (IB)wherein R1, R2, R3, R4, R5, R6, R7and R8are as defined herein, or a tautomer prodrug, solvate, or salt thereof; pharmaceutical compositions containing such compounds, and methods of modulating the glucocorticoid receptor function and methods of treating disease-states or conditions mediated by the glucocorticoid receptor function or characterized by inflammatory, allergic, or proliferative processes in a patient using these compounds.
REFERENCES:
patent: 4880839 (1989-11-01), BP
patent: 5039691 (1991-08-01), Spagnuolo et al.
patent: 5688810 (1997-11-01), Jones et al.
patent: 6323199 (2001-11-01), Lehmann et al.
patent: 6329534 (2001-12-01), Kym et al.
patent: 6380223 (2002-04-01), Dow et al.
patent: 6436986 (2002-08-01), Kym et al.
patent: 6506766 (2003-01-01), Coghlan et al.
patent: 6583180 (2003-06-01), Link et al.
patent: 2002/0077356 (2002-06-01), Jaroch et al.
patent: 2002/0156311 (2002-10-01), Link
patent: 2003/0105099 (2003-06-01), Graupe
patent: 2003/0232823 (2003-12-01), Betageri et al.
patent: 2004/0010020 (2004-01-01), Kirrane et al.
patent: 2004/0010148 (2004-01-01), Kirrane et al.
patent: 2004/0023999 (2004-02-01), Bekkali et al.
patent: 2004/0029932 (2004-02-01), Bekkali et al.
patent: 2004/0097574 (2004-05-01), Marshall
patent: 900594 (1984-09-01), None
patent: 0 154 528 (1985-11-01), None
patent: 0 154 528 (1985-11-01), None
patent: 0 311 447 (1988-10-01), None
patent: 0 253 500 (1991-02-01), None
patent: 0 253 503 (1991-12-01), None
patent: 0 154 528 (1995-11-01), None
patent: 2 146 987 (1985-05-01), None
patent: 11/080131 (1999-03-01), None
patent: 11 080131 (1999-03-01), None
patent: 0 311 447 (1988-10-01), None
patent: WO 96/19458 (1996-06-01), None
patent: WO 97 27852 (1997-08-01), None
patent: WO 97/27852 (1997-08-01), None
patent: WO 9727852 (1997-08-01), None
patent: WO 98/54159 (1998-12-01), None
patent: WO 99/33786 (1999-07-01), None
patent: WO 99/41256 (1999-08-01), None
patent: WO 99/63976 (1999-12-01), None
patent: WO 00 32584 (2000-06-01), None
patent: WO 00/32584 (2000-06-01), None
patent: WO 0032584 (2000-06-01), None
patent: WO 00/66522 (2000-11-01), None
patent: WO 02/02565 (2002-01-01), None
patent: WO 02/10143 (2002-02-01), None
patent: WO 02/051983 (2002-07-01), None
patent: WO 02/064550 (2002-08-01), None
Coghlan et al. J. Med. Chem. 2001, 44, 2879-2885.
Hamann, Lawrence ,et al ; Discovery of a potent, Orally active, Nonsteroidal Androgen receptor Agonist: 4-Ethyl-1,2,3,4-tetrahydro-6-(trifluoromethyl)-8-pyridono 5,6-gl-quinoline(LG121071), J. Med. Chem, 1999, 42, 210-212.
Pooley, Charlotte, et al; Discovery and Preliminary SAR Studies of a Novel Nonsteroidal Progesterone Receptor Antagonist Pharmacophore, J. Med. Chem 1998, 41, 3461-3466.
Edwards, James, P. et al; 5-Aryl-1,2-dihydro-5H-chromeno[3,4-f]quinolines as Potent, Orally Active, Nonsteroidal Progestgerone Receptor Agonists; The Effect of D-Ring Substituents, J. Med. Chem, 1998,41, 303-310.
Zhi, Lin, et al; 5-Aryl-1,2-dihydro-5H-chromeno[3,4-f]quinolines: A Novel Class of Nonsteroidal Human Progesterone Receptor Agonists, J. Med. Chem 1998, 41,291-302.
Zhi, Lin; et al 5-Aryl-1,2,3,4-tetrahydrochromeno[3,4-f]quinolin-3-ones as a Novel Class of Nonsteroidal Human Progesterone Receptor Agonists; J. Med. Chem 1998, 41, 4354-4359.
Tegley, Christopher, et al; 5-Benzylidene 1,2-Dihydrochromeno[3,4-f ]quinolines, A Novel Class of Nonsteroidal Human Progesterone Receptor Agonists; J. Med. Chem. 1998, 41, 4354-4359.
Edwards, James, P. et al; Preparation, Resolution and Biological Evaluation of 5-Aryl-1,2 -diydro -5h-chromeno [3,4 -f ] quinolines as Potent, Orally Active, Nonsteroidal Progestgerone Receptor Agonists; J. Med. Chem 1998, 41, 2779-2785.
Hamann, Lawrence, et al; Synthesis and Biological Activity of Novel Series of Nonsteroidal, Peripherally Selective Androgen Receptor Antagonists Derived from 1,2-Dihydropyridono [5,6-g ] quinolines J. Med. Chem 1998, 41, 623-639.
English Translation of WO/02/10143.
Abstract for JP 11 080131—XP-002255050.
Beilstein No. 7067440 —J. Chem. Soc., Dalton, Trans., vol. 22, 1994, pgs. 3202-3210; XP-002255049.
Barnes, P. J.; “anti -inflammatory actions of glucocorticoids: molecular mechanisms”; clinical science, 1998, vol. 94, pp. 557-572.
Barnes, P.J. et al; “anti-infammatory actions of steroids: molecular mechanisms ”; Trends Pharm. Sci. 1993, 14, pp. 436-441.
Reichardt, H.M. et al; “DNA Binding of the Glucocorticoid Receptor is Not Essential for Survival ”; Cell, 1998, 93 pp. 531-541.
Tronche, F. et al; “Genetic dissection of glucocorticoid receptor function in mice”; Curr. Opin. in Genetics and Dev. 1998, 8, pp. 532-538.
Bamberger, C. M. et al; “molecular mechanisms of dissociative glucocorticoid activity” Eur. J. Clin. Invest., 2000, 30 (Suppl. 3), pp. 6-9.
Friedman, J. E., et al; “Phosphoenolpyruvate Carboxykinase (GTP) Gene Transcription and Hyperglycemia Are Regulated by Glucocorticoids in Genetically Obese db/db Transgenic Mice*”, J biol. chem., 1997, 272 pp. 31475-31481.
Casella, Luigi, et al. “Cytochrome c Oxidase Models; Synthesis and Reactivity of Iron (III)-Copper (II) Complexes of Deuterohaemin-Polybenzimidazole Dinucleating Ligands ” J. Chem. Soc. Dalton Trans, 1994, vol. 22, pp. 3202-3210.
Bekkali, Y., et al; Application entitled Glucocorticoid Mimetics, Methods of Making Them, Pharmaceutical Compositions and Uses Thereof, accorded U.S. Appl. No. 10/639,131.
Beilstein No. 7067440 —J. Chem. Soc., Dalton, Trans., vol. 22, 1994, pp. 3202-3210; XP-002255049.
Barnes, P. J.; “Anti-infammatory actions of glucocorticoids: molecular mechanisms ”; clinical Science, 1998, vol. 94, pp. 557-572.
Barnes, P.J. et al; “Anti-inflammatory actions of steroids: molecular mechanisms”; Trends Pharm. Sci. 1993, 14, pp. 436-441.
Parente, L.; “The develpment of synthetic glucocorticoids”; Glucocorticolds, 2001, pp. 35-54.
Toogood, J.H.; “Glucocorticoids and asthma”; Glucocortiocids, 2001, pp. 161-174.
Oakley, R.H. et al; “the Glucocorticoid receptor: expression, function, and regulation of glucocorticoid responsiveness”; Glucocorticoids, 2001, pp. 55-80.
Evans, R.M.; “The Steroid and Thyroid Hormone Receptor Superfamily”; Science, 1988, 240, pp. 889-895.
Heck, S. et al; “A distinct modulating domain in glucocorticold receptor monomers in the repression of activity of the transcription factor AP-1”; EMBO J., 1994, 17, pp. 4087-4095.
Reichardt, H.M. et al; “DNA Binding of the Glucocorticoid Receptor Is Not Essential for Survival”; Cell, 1998, 93, pp. 521-541.
Tronche,F.et al; “Genetic dissection of Glucocorticoid receptor function in mice”;Curr. Opin. In Genetics and Dev. 1998, 8, pp. 532-538.
Bamberger, C. M. et al; “Motrcular mechanisms of dissociative glucocorticoid activity” Eur. J. Clim. Invest., 2000, 30 (Suppl. 3), pp. 6-9.
Friedman, J. E., et al; “Phosphoenolpyruvate carboxykinase (GTP) Gene Transcription and Hyperglycemia Are Regulated by Glucocorticoids in Genetically Obese db/db Transgenic Mice”; J. biol. chem., 1997, 272, pp. 31475-31481.
Casella, Luigi, et al. “Cytochrome c Oxidase Models; Synthesis and Reactivity of Iron (111)-Copper(11) Complexes of Deuterohaemin-Polybenzimidazole Dinucleatind Ligandx ” J. Chem. Soc. Dalton Trans, 1994, Vol. 22. pp. 3202-3210
Bekkali, Y., et al; Application entitled Glucocorticoid Mimetics, Methods of Making Them, Pharmaceutical Compostions and Uses Thereof, accorded U.S. Appl. No. 10/639,131.
Kuzmich, D., et al; Application entitled Glucocorticoid Mimetics, Methods of Making Them, Pharmaceutical Compositions and Uses Thereof, accorded U.S. Appl. No. 10/739.208.
Cywin, C. et al; Application entitled Glucocorticoid Mimetics, Methods of making Them, Pharmaceutical Compositions and Uses Thereof, accorded U.S Appl. No. 10/785,222.
Kirrane, Jr. Thomas Martin
Kuzmich Daniel
Proudfoot John Robert
Razavi Hossein
Thomson David
Boehringer Ingelheim Pharmaceuticals Inc.
Bottino Anthony P.
Datlow Philip I.
Huang Evelyn Mei
Morris Michael P.
LandOfFree
Glucocorticoid mimetics, methods of making them,... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Glucocorticoid mimetics, methods of making them,..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Glucocorticoid mimetics, methods of making them,... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3569957